Leaflet ENTANIDDA 200mg film-coated tablets
Indicated for: Parkinson's disease
Route of administration: oral
Substance: entacapone (antiparkinsonian agent)
ATC: N04BX02 (Nervous system | Dopaminergic agents | Other dopaminergic agents)
This medicine may affect your ability to drive or use machines.
This medicine may cause dizziness or vertigo.
May lower blood pressure and increase the risk of falls.
This medicine may cause drowsiness or reduced alertness.
Entacapone is a medication used in the treatment of Parkinson's disease, administered together with levodopa to increase its effectiveness. It works by inhibiting an enzyme that breaks down levodopa in the body, thus prolonging its effect and improving motor fluctuations in patients.
Entacapone is taken orally, usually with each dose of levodopa, as directed by your doctor. It is important for the patient to follow the treatment schedule and not to stop administration without medical advice.
Side effects may include diarrhea, nausea, reddish-brown urine discoloration, fatigue, or involuntary movements. Rarely, allergic reactions or liver disorders may occur. Regular medical monitoring is recommended during treatment.
Entacapone helps control the symptoms of Parkinson's disease and improve quality of life, but requires correct administration and medical supervision to prevent complications.
General data about ENTANIDDA 200mg
- Substance: entacapone
- Date of latest medicines list: 01-07-2013
- Product code: W55503001
- Concentration: 200mg
- Pharmaceutical form: film-coated tablets
- Quantity: 10
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.